Evaluation of efficacy and safety of external beam radiotherapy in patients with colorectal cancer liver metastases.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
169 patients with CRLM undergoing medical therapy were enrolled.
I · Intervention 중재 / 시술
EBRT—36 with SBRT and 29 with IMRT targeting liver metastases, and were included in the local control analysis
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[OBJECTIVE] This study aimed to evaluate the therapeutic efficacy of external beam radiotherapy (EBRT) in patients with colorectal cancer liver metastases (CRLM) who were either ineligible for or decl
APA
Cao P, Wang X, et al. (2026). Evaluation of efficacy and safety of external beam radiotherapy in patients with colorectal cancer liver metastases.. Discover oncology, 17(1), 265. https://doi.org/10.1007/s12672-026-04425-2
MLA
Cao P, et al.. "Evaluation of efficacy and safety of external beam radiotherapy in patients with colorectal cancer liver metastases.." Discover oncology, vol. 17, no. 1, 2026, pp. 265.
PMID
41528405 ↗
Abstract 한글 요약
[OBJECTIVE] This study aimed to evaluate the therapeutic efficacy of external beam radiotherapy (EBRT) in patients with colorectal cancer liver metastases (CRLM) who were either ineligible for or declined surgical resection. Each patient received either intensity-modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT), determined according to tumor size and anatomical location.
[MATERIALS AND METHODS] Between July 2014 and March 2024, 169 patients with CRLM undergoing medical therapy were enrolled. Propensity score matching (PSM) was used to balance baseline characteristics, resulting in 61 matched pairs ( = 122) for survival and toxicity analyses. Among all patients, 65 received EBRT—36 with SBRT and 29 with IMRT targeting liver metastases, and were included in the local control analysis.
[RESULTS] After PSM ( = 61 per group), patients treated with “EBRT + medical” therapy exhibited significantly higher survival than those only receiving medical therapy. The median OS was longer in the EBRT group (37.0 vs. 20.8 months, < 0.001), and PFS was superior too (14.8 vs. 8.17 months, = 0.001). Local control rates were 82.9% and 67.9% for SBRT at 1 and 2 years, respectively, and 75.5% and 50.6% for IMRT, respectively. EBRT was well tolerated; no radiation-induced liver disease occurred, and no significant differences in adverse event incidence were observed between the medication-only and combined-EBRT groups.
[CONCLUSION] EBRT represents a safe and effective local treatment option for patients with unresectable CRLM. This study is the first to systematically evaluate IMRT in this population and the first PSM-based comparison of radiotherapy versus no radiotherapy, providing robust evidence for the independent therapeutic benefit of EBRT, however, the retrospective design and potential residual confounding should be considered when interpreting this finding.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12672-026-04425-2.
[MATERIALS AND METHODS] Between July 2014 and March 2024, 169 patients with CRLM undergoing medical therapy were enrolled. Propensity score matching (PSM) was used to balance baseline characteristics, resulting in 61 matched pairs ( = 122) for survival and toxicity analyses. Among all patients, 65 received EBRT—36 with SBRT and 29 with IMRT targeting liver metastases, and were included in the local control analysis.
[RESULTS] After PSM ( = 61 per group), patients treated with “EBRT + medical” therapy exhibited significantly higher survival than those only receiving medical therapy. The median OS was longer in the EBRT group (37.0 vs. 20.8 months, < 0.001), and PFS was superior too (14.8 vs. 8.17 months, = 0.001). Local control rates were 82.9% and 67.9% for SBRT at 1 and 2 years, respectively, and 75.5% and 50.6% for IMRT, respectively. EBRT was well tolerated; no radiation-induced liver disease occurred, and no significant differences in adverse event incidence were observed between the medication-only and combined-EBRT groups.
[CONCLUSION] EBRT represents a safe and effective local treatment option for patients with unresectable CRLM. This study is the first to systematically evaluate IMRT in this population and the first PSM-based comparison of radiotherapy versus no radiotherapy, providing robust evidence for the independent therapeutic benefit of EBRT, however, the retrospective design and potential residual confounding should be considered when interpreting this finding.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12672-026-04425-2.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.
- Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer.
- Manganese-engineered Lactobacillus Reuteri with enhanced antitumor and immunomodulatory activities for colorectal cancer prevention and treatment.
- Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target.
- Evaluation of Magnetic Resonance Imaging for Microsurgical Efficacy and Relapse of Rolandic Meningioma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer Liver Metastases (CRLM).
- The role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives.
- Long-term outcomes of external beam radiotherapy combined with high-dose-rate brachytherapy boost in intermediate- and high-risk prostate cancer.
- Robustness Comparison of the Virtual Bolus Method and Robust Optimization in Postmastectomy Radiation Therapy Using Volumetric Modulated Arc Therapy.
- From Development to Implementation: A Systematic Review on the Current Maturity Status of Artificial Intelligence Models for Patients with Colorectal Cancer Liver Metastases.
- Predicting intrahepatic recurrence of colorectal cancer liver metastases after curative hepatectomy using a machine learning model with data integration of ultrasound radiomics and clinicopathological parameters.